PCSK9 Polymorphism and Risk of Cardiac Rupture
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Aug 15, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a specific gene called PCSK9 and its possible connection to a serious condition known as post-infarction heart rupture, which can happen after a heart attack. Researchers want to understand why some patients experience this dangerous complication while others do not, especially since it can occur shortly after a heart attack. They think that variations in the PCSK9 gene might play a role in how the heart reacts to damage from a heart attack.
To participate in this study, you should be between the ages of 65 and 74 and have been diagnosed with either a heart attack with a certain type of heart damage (known as ST elevation) or a heart attack that has led to cardiac rupture. If you join the trial, you will help researchers learn more about the heart's healing process and how genetic differences might influence recovery after a heart attack. This could lead to better treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • clinical diagnosis of acute myocardial infarction with ST sopra-elevation (control group)
- • clinical diagnosis of acute myocardial infarction complicated by cardiac rupture
- Exclusion Criteria:
- • absence of coronary artery disease
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Varese, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials